ADMA Biologics, Inc. (ADMA): Cost of Revenue
$217.41M
Year ended 2025-12-31
$180.81M
Trailing 12 months to 2026-06-30
+22.3%
3-year compound annual growth
+28.8%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $217.41M | +5.1% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $206.90M | +22.2% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $169.27M | +42.5% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $118.81M | +48.9% | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | $79.77M | +30.1% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $61.29M | +55.2% | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | $39.50M | -6.4% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $42.19M | +44.7% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $29.16M | n/m | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | $1.61M | n/a | 2018-03-29, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $217.41M | +5.1% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $5.09M | +86.3% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $185.57M | +3.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $352.01M | -2.2% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $19.07M | +55.5% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $71.36M | -1.0% |
| Vericel Corp (VCEL) | 2025-12-31 | $70.66M | +8.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $173.18M | +85.7% |
| Novavax Inc (NVAX) | 2025-12-31 | $73.04M | -64.0% |
Compare ADMA, IMCR, TWST, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗